News | July 15, 2008

MIV Provides Study Update on Its Ultra-Thin Protea Stent Platform

July 17, 2008 - MIV Therapeutics Inc. today said its Protea ultra-thin cobalt-alloy bare metal stent has excelled in animal studies, reportedly showing the Protea is statistically superior to one of the best and most deliverable cobalt-alloy bare metal stents on the market.

The Protea is the company’s next generation bare metal stent with a strut thickness of 65 microns, a fixed geometry and uniform cell size for homogeneous delivery of drug to the local tissue, and a superior surface finish when compared to currently available cobalt alloy stents.

At one month following deployment, quantitative coronary angiography (QCA) showed percent diameter stenosis was significantly less for Protea (2±5 percent vs. 17±16 percent, p=0.032). By histomorphometry, intima thickness (0.11±0.05 mm vs. 0.23±0.11 mm, p=0.003) and percent area stenosis (19±1 vs. 32±11 percent, respectively, p=0.004) were also significantly lower for Protea. The strut injury score was low and similar between the two groups. QCA percent stenosis; intima thickness; and percent area stenosis of overlapping Protea stents were 3±3 percent, 0.13±0.02 mm, and 22±4 percent, respectively. Stable fibrocellular neointimal incorporation of all stents including overlapped Protea, with complete endothelialization and minimal inflammation, was seen at one month.

The Protea is used as the bare metal stent platform for the VESTAsync drug eluting stent in the VESTASYNC II trial. The company said in addition to a superior surface finish due to a proprietary finishing technique and thinner struts, the surface area of the Protea was designed to be the same as that of the GenX, which allows the company to use the same dose and drug delivery system for both stents.

For more information:

Related Content

FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral| March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
Sponsored Content | Videos | Stents Bifurcation| March 06, 2017
This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent.
Overlay Init